Xiromed LLC today announced that it has launched the first three injectable products from its strategic collaboration with Gland Pharma Ltd of Hyderabad, India: Irinotecan Injection USP, 20mg/mL, Glycopyrrolate Injection USP, 0.2mg/mL, and Neostigmine Methylsulfate Injection USP, available in two strengths: 5 mg/10 mL (0.5mg/mL) and 10 mg/10 mL (1mg/mL). These are the first injectable products Xiromed has launched in the US market, and represent the first three product launches of a basket of injectable products that Xiromed and Gland have in partnership.
Irinotecan Injection USP, 20mg/mL is a generic equivalent to Camptosar® and is available in a 2mL and 5mL single-dose vial. According to IQVIA™, market sales for Camptosar® and its generic equivalents were $15.7m for the twelve month period ending in June, 2020.
Glycopyrrolate Injection USP, 0.2mg/mL is a generic equivalent to Robinul® and is available in 1mL and 2mL single-dose vials, and 5mL and 20mL multi-dose vials. Market sales for Robinul® and its generic equivalents were $60.8m for the twelve month period ending in June, 2020, as reported by IQVIA™.
Neostigmine Methylsulfate Injection USP, is a generic equivalent to Bloxiverz® and is available in 5 mg/10 mL multi-dose vial and 10 mg/10 mL multi-dose vial. Market sales for Bloxiverz® and its generic equivalents were $23.2m for the twelve month period ending in June, 2020, per IQVIA™.
“This is an exciting day for Xiromed, as we launch our first injectable products into the US market, in collaboration with our strategic development and manufacturing partner, Gland Pharma,” commented Xiromed CEO, Narasimhan Mani. “Xiromed has built a strong portfolio of injectable products, both through strategic partnerships, as well as through leveraging our internal expertise. Xiromed has a seasoned institutional sales team eager to provide quality generic injectable products to our institutional customers, and these three products are the first in a robust portfolio of injectables that we intend to launch in the near-term.”
Xiromed, LLC, located in Florham Park, NJ, is the US Generic Pharmaceuticals division of Insud Pharma, S.L., a global pharmaceutical company headquartered in Madrid, Spain. Xiromed is focused on developing and commercializing high quality generic products for the US market. In addition to its commercial portfolio of generics available in the United States, Xiromed has a robust development pipeline of generic pharmaceutical products, which includes injectable, inhalation and complex generic products. Learn more at http://www.xiromed.com/usa/